Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Home  /  Forum  /  uniQure  /  Press relaeses

Ontvang nu dagelijks onze kooptips!

word abonnee

uniQure« Terug naar discussie overzicht

Press relaeses

39 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  1. [verwijderd] 13 juni 2014 17:54

    finance.yahoo.com/news/uniqure-announ...

    uniQure Announces Will Lewis as New Board Member
    GlobeNewswire
    uniQure June 12, 2014 6:15 AM

    AMSTERDAM, Netherlands, June 12, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leader in human gene therapy, today announced that Will Lewis has joined uniQure's Supervisory Board as of June 11th, 2014. Mr. Lewis has been serving as President and Chief Executive Officer and as a member of the Board of Directors of Insmed, a biopharmaceutical company specialized in inhalation therapies for orphan lung diseases, since 2012.

    "Will has a tremendous track record in achieving success for companies much like ours," said Jorn Aldag, CEO of uniQure. "His exceptional experience in the field of orphan diseases as well as his broad knowledge of the US and European financial markets will be of high value to the company."

    "uniQure is at the forefront of gene therapy, not only aiming at curative treatments for orphan diseases but seeking to have a broader impact on human health by developing therapies to treat diseases such as Parkinson's," commented Will Lewis, MBA/JD. "Having been involved in both the scientific and financial aspects of management in the past, I am committed to bring my expertise in both areas to uniQure."

    Mr. Lewis has more than 20 years of executive experience in the pharmaceutical and finance industries both in the US and internationally. He is the former Co-Founder, President and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. During his tenure at Aegerion, Mr. Lewis played a pivotal role in re-orienting the company's strategy to focus on orphan disease indications. Prior to Aegerion, Mr. Lewis spent 10 years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo. During his time in banking, he was involved in a broad range of domestic and international capital raises and advisory work valued at more than $20 billion.

    Mr. Lewis also serves as a member of the Board of Directors of Oberlin College and is a member of the Visiting Committees of the Weatherhead School of Management of Case Western Reserve University and The Hawken School. Mr. Lewis holds a Bachelor of Arts degree cum laude from Oberlin College and a Master of Business Administration/Juris Doctor with Honors from Case Western Reserve University. Prior to attending graduate school he worked in the Foreign Service for the US Government.

    About uniQure
    uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com

    FORWARD-LOOKING STATEMENTS
    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates, the risk of delay or failure to successfully commercialize or obtain further regulatory approval of Glybera, and the risk that our collaborations with Chiesi or our other collaboration partners will not continue or will not be successful. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Form 20-F filed with the Securities and Exchange Commission dated April 25, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

    uniQure:
    Aicha Diba
    Investor Relations
    Direct : +31 20 240 6100
    Main: +31 20 566 7394
    IR@uniQure.com

    Media inquiries:
    Gretchen Schweitzer
    MacDougall Biomedical Communications
    Direct: +49 172 861 8540
    Main: +1 781 235 3060
    gschweitzer@macbiocom.com

    HUG#1792441

  3. [verwijderd] 1 juli 2014 11:44

    finance.yahoo.com/news/uniqure-secure...

    uniQure Secures Additional $10M Venture Loan from Hercules Capital
    Restructured Venture Debt Financing for Expansion and Advancement of Gene Therapy Pipeline
    GlobeNewswire
    uniQure 15 minutes ago

    AMSTERDAM, the Netherlands, July 1, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leader in human gene therapy, today announced the closing of an additional $10 million venture debt loan with Hercules Technology Growth Capital, Inc. (HTGC), increasing the total loan amount to $20 million including the initial $10 million that uniQure announced in July 2013.

    "The expansion of our original agreement with Hercules and its restructuring to incorporate further beneficial terms for uniQure provide us with greater balance sheet strength and flexibility. We will devote our additional capital both to rapidly advancing our pipeline and to accessing early-stage opportunities that will leverage our gene therapy platform and manufacturing expertise," commented Jorn Aldag, uniQure Chief Executive Officer. "Accessing the best third party programs in early development enables us to further expand our high quality pipeline, sustaining the Company's leadership position in gene therapy."

    The initial agreement with HTGC earmarked a portion of the venture debt financing to support the build-out of a state-of-the-art AAV-based gene therapy manufacturing facility in Lexington, MA. uniQure anticipates the facility to be fully operational in 2015.

    About uniQure

    uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com

    About Hercules Technology Growth Capital

    Hercules Technology Growth Capital, Inc. (HTGC) is the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy and renewables technology industries, at all stages of development. Since inception (December 2003), Hercules has committed more than $4.2 billion to over 270 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. More information on the company can be found at www.htgc.com.

    FORWARD-LOOKING STATEMENTS

    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates, the risk of delay or failure to successfully commercialize or obtain further regulatory approval of Glybera, and the risk that our collaborations with Chiesi or our other collaboration partners will not continue or will not be successful. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Form 20-F filed with the Securities and Exchange Commission dated April 25, 2014. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

    uniQure:
    Aicha Diba
    Investor Relations
    Direct: +31 20 240 6100
    Main: +31 20 566 7394
    IR@uniQure.com

    Media inquiries:
    Gretchen Schweitzer
    MacDougall Biomedical Communications
    Direct: +49 172 861 8540
    Main: +1 781 235 3060
    gschweitzer@macbiocom.com
  5. forum rang 10 DeZwarteRidder 4 augustus 2014 18:57

    Chiesi and uniQure Provide Update on Glybera(r) Launch
    GlobeNewswire
    uniQure 5 hours ago

    AMSTERDAM, the Netherlands, and PARMA, Italy, Aug. 4, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leader in human gene therapy, and Chiesi Farmaceutici S.p.A. ("Chiesi"), a leading international pharmaceutical company, today provided an update on preparations relating to the launch of Glybera(R) (alipogen tiparvovec), the first gene therapy product approved in the European Union, for the treatment of the orphan disease lipoprotein lipase deficiency (LPLD). Chiesi has exclusive rights to commercialize Glybera in the EU and selected additional territories. Expanding on the original launch strategy, Chiesi and uniQure decided to include in the pricing and reimbursement applications for launch, the six-year follow-up pancreatitis data from the study AMT 011-05, announced June 3, 2014. As a consequence, Chiesi now expects to launch Glybera in the fourth quarter of 2014/first quarter of 2015.

    "We are fully supportive of Chiesi's approach to include additional data demonstrating multiyear benefit for a one time treatment in our pricing and reimbursement documentation. Adding long-term data will significantly strengthen the quality of the application," said Jorn Aldag, CEO of uniQure.

    Chiesi CEO Ugo Di Francesco added: "Whilst pricing and reimbursement discussions are on-going, Chiesi has commenced the setup of a number of expert treatment centres which will be able to offer Glybera for the appropriate patients and manage them post treatment."

    Developed by uniQure, Glybera was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with LPLD, a potentially life-threatening, orphan metabolic disease. Glybera currently is not approved for use outside of the European Union.

    Glybera is indicated for the treatment of adult patients diagnosed with familial LPLD confirmed by genetic testing and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. LPLD results in hyper-chylomicronemia, or dramatic and potentially life-threatening increases in the level of large fat-carrying particles, called chylomicrons, in the blood after eating. In many cases, LPLD and the associated elevated levels of chylomicrons can cause acute and potentially life-threatening inflammation of the pancreas, known as pancreatitis, thus leading to frequent hospitalizations. Recurrent pancreatitis can lead to chronic abdominal pain, pancreatic insufficiency - which is an inability to properly digest food due to a lack of digestive enzymes made by the pancreas -, and diabetes. There is no other approved treatment for LPLD.
  7. [verwijderd] 4 augustus 2014 23:38
    eigenlijk is het een hele goede reactie...op dagen zonder nieuws ging het soms veel harder onderuit.

    Het wordt voor kennisgeving aangenomen en de lage omzet vandaag is nietszeggend.

    ander algemeen vraagje: is bij iemand de conversie van certificaten naar aandelen al gewoon afgerond?

    Bij mij (ALEX)namelijk nog niet en dat zou wellicht het ontbreken van de enorme verkoopdruk kunnen verklaren als dat voor iedere certificaathouder geldt... ;-)
  8. [verwijderd] 5 augustus 2014 12:26
    quote:

    invoorentegenspoed schreef op 4 augustus 2014 23:38:

    eigenlijk is het een hele goede reactie...op dagen zonder nieuws ging het soms veel harder onderuit.

    Het wordt voor kennisgeving aangenomen en de lage omzet vandaag is nietszeggend.

    ander algemeen vraagje: is bij iemand de conversie van certificaten naar aandelen al gewoon afgerond?

    Bij mij (ALEX)namelijk nog niet en dat zou wellicht het ontbreken van de enorme verkoopdruk kunnen verklaren als dat voor iedere certificaathouder geldt... ;-)
    Dat laatste was tevens mijn gedachte, denk niet dat er al veel geconverteerd is. Bij mij iig ook nog niet (DeGiro). We zullen zien of de omzetten vandaag een stap gaan maken.
  13. [verwijderd] 5 augustus 2014 18:03
    quote:

    DeZwarteRidder schreef op 5 augustus 2014 16:39:

    [...]

    Wat een feest...!!

    En nu nog proberen te verkopen....
    Hahaha, lolbroek. Dat was een mededeling voor aandeelhouders, waar jij blijkbaar niet onder valt. Waarom investeer jij zoveel tijd in dit forum als je geen belang hebt? Ofwel je bent een slechte verliezer (die flink het schip in is gegaan met AMT oid) ofwel je hebt geen andere hobbies.
  14. henrico26 5 augustus 2014 18:16
    Bij Binck zijn ze nog niet geconverteerd en dus ook nog niet te verhandelen. Het probleem is bekend en men is er mee bezig, misschien wel een tip wanneer je ook Binck rekeninghouder bent om je te melden bij Binck en je rekeningnummer door te geven. Wellicht dat het probleem dan opgeschaald wordt wanneer meerdere certificaathouders zich melden en ze eerder geconverteerd worden. Ik heb om een verwachting gevraagd wanneer dit opgelost zou zijn, hier kon men nog geen uitspraak over doen. Er is een ander team die dit behandeld, maar ik word als het goed is teruugebeld.
  15. [verwijderd] 5 augustus 2014 20:55
    quote:

    Rien.Nevaplus schreef op 5 augustus 2014 18:03:

    [...]

    Hahaha, lolbroek. Dat was een mededeling voor aandeelhouders, waar jij blijkbaar niet onder valt. Waarom investeer jij zoveel tijd in dit forum als je geen belang hebt? Ofwel je bent een slechte verliezer (die flink het schip in is gegaan met AMT oid) ofwel je hebt geen andere hobbies.
    De spijker op zijn kop: eenzame oude mannen die als hobby hebben om te zieken op forums.
  17. PinkPanther 6 augustus 2014 16:59
    Ik had mijn certificaten nog op mijn npex rekening laten staan. Ik zie zojuist dat deze zijn omgezet naar gewone QURE aandelen. Nu even kijken per wanneer ik ze laat overzetten naar de ING Bank. Volgens de berichtgeving van zowel npex als de ING moet het binnenkort mogelijk zijn om via de ING in aandelen QURE te handelen. Dit is op het moment nog niet het geval. Als er iemand meer info heeft, bv. een datum, dan verneem ik het graag.
  18. henrico26 6 augustus 2014 18:03
    Ik heb net met Binck gebeld en om een update gevraagd, naar het blijkt moet de uitleverende instantie de stukken/aandelen nog leveren. Dit had officieel gisteren moeten gebeuren, maar bij buitenlandse instellingen duurt het soms nog wel een dag later. Of we ze vandaag bij Binck nog ontvangen is moeilik te zegge, ik begreep van de medewerkers dat men er wel bovenop zit.
  19. Rosj Hasjana 6 augustus 2014 18:52
    Hartelijk dank voor uw e-mail. U heeft een vraag over de omzetting van uw aandelen Uniqure. Op dit moment is de omzetting van uw aandelen Uniqure ingang. Wij wachten echter nog op de aandelen. Zodra wij de aandelen hebben ontvangen worden deze in uw portefeuille gedeponeerd.

    Ik vertrouw erop u met deze informatie van dienst te zijn.

    Vragen?
    Als u nog vragen of opmerkingen heeft, zijn wij u uiteraard graag van dienst. De medewerkers van de Servicedesk zijn bereikbaar op werkdagen van 8:00 uur tot 22:00 uur en op zaterdag van 10:00 uur tot 17:00 uur op telefoonnummer 020 - 521 81 80 of per e-mail op info@alex.nl.
  20. henrico26 6 augustus 2014 19:55
    Nog even afwachten dus, in ieder geval een prettige bijkomstigheid dat dat Uniqure vandaag weer eens in de plus staat. Koers is afgelopen weken weer aardig teruggevallen en leek zich net mooi te gaan herstellen. Ik ben benieuwd wat de meeste certificaathouders die aandelen krijgen er tegen deze koers mee gaan doen. Ik ben wel voornemens om ze even vast te houden de komende tijd en wil ze nog niet kwijt voor deze koers. Er moet nog meer in het vat zitten...
39 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 865,35 0,00%
EUR/USD 1,0677 +0,06%
FTSE 100 7.847,99 +0,35%
Germany40^ 17.771,70 +0,01%
Gold spot 2.374,77 +0,58%
NY-Nasdaq Composite 15.683,37 -1,15%

Stijgers

AALBER...
0,00%
ABN AM...
0,00%
Accsys
0,00%
ACOMO
0,00%
ADYEN NV
0,00%

Dalers

AALBER...
0,00%
ABN AM...
0,00%
Accsys
0,00%
ACOMO
0,00%
ADYEN NV
0,00%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!